Glox Therapeutics awarded grant towards antibiotics against antimicrobial-resistant pathogens
Glox Therapeutics, involved in the development of precision antibiotic therapies based on naturally occurring bacteriocins, announced it has secured £1 million in grant funding from PACE (Pathways to Antimicrobial Clinical Efficacy).